| Dr Unknown Bilori, MD | |
|
111 Wakelee Ave, Ansonia, CT 06401-1151 | |
| (203) 308-2781 | |
| (203) 308-2726 |
| Full Name | Dr Unknown Bilori |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 18 Years |
| Location | 111 Wakelee Ave, Ansonia, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760762090 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 53166 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Griffin Hospital | Derby, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Griffin Faculty Physicians Inc | 7618871997 | 107 |
News Archive
A new study shows that concern about infertility resulting from breast cancer therapy influenced treatment decisions in nearly one-third of young patients.
The American Diabetes Association today issued the following statement in response to the passage by the Senate of the "Stem Cell Research Enhancement Act" (S.5), which will accelerate stem cell research by easing existing funding restrictions and supporting research that uses embryonic stem cells, while maintaining strict ethical guidelines.
The hepatitis C therapy peginterferon alfa-2b, when given as low-dose maintenance therapy, can prevent disease progression in certain patients who failed previous interferon-based hepatitis C therapies and have advanced liver disease, according to findings from a large, four-year study presented today at the 43rd annual meeting of the European Association for the Study of the Liver (EASL).
The National Journal assessed President Barack Obama's progress on his health care campaign promises and gave him a score of 47. "As a candidate, Barack Obama made a series of fairly specific promises on health care ($10 billion a year for health IT, loan forgiveness for rural doctors) and drew some bold lines in the sand (universal coverage, prohibitions on insurers from discriminating).
GenSpera, Inc. announced that the first patient was dosed in the ongoing Phase I clinical study of its chemotherapeutic agent, G-202, at the Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio in San Antonio, Texas.
› Verified 7 days ago
| Entity Name | Griffin Faculty Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598755605 PECOS PAC ID: 7618871997 Enrollment ID: O20031120000158 |
News Archive
A new study shows that concern about infertility resulting from breast cancer therapy influenced treatment decisions in nearly one-third of young patients.
The American Diabetes Association today issued the following statement in response to the passage by the Senate of the "Stem Cell Research Enhancement Act" (S.5), which will accelerate stem cell research by easing existing funding restrictions and supporting research that uses embryonic stem cells, while maintaining strict ethical guidelines.
The hepatitis C therapy peginterferon alfa-2b, when given as low-dose maintenance therapy, can prevent disease progression in certain patients who failed previous interferon-based hepatitis C therapies and have advanced liver disease, according to findings from a large, four-year study presented today at the 43rd annual meeting of the European Association for the Study of the Liver (EASL).
The National Journal assessed President Barack Obama's progress on his health care campaign promises and gave him a score of 47. "As a candidate, Barack Obama made a series of fairly specific promises on health care ($10 billion a year for health IT, loan forgiveness for rural doctors) and drew some bold lines in the sand (universal coverage, prohibitions on insurers from discriminating).
GenSpera, Inc. announced that the first patient was dosed in the ongoing Phase I clinical study of its chemotherapeutic agent, G-202, at the Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio in San Antonio, Texas.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Unknown Bilori, MD 67 Maple Ave, Derby, CT 06418-1328 Ph: (203) 732-1330 | Dr Unknown Bilori, MD 111 Wakelee Ave, Ansonia, CT 06401-1151 Ph: (203) 308-2781 |
News Archive
A new study shows that concern about infertility resulting from breast cancer therapy influenced treatment decisions in nearly one-third of young patients.
The American Diabetes Association today issued the following statement in response to the passage by the Senate of the "Stem Cell Research Enhancement Act" (S.5), which will accelerate stem cell research by easing existing funding restrictions and supporting research that uses embryonic stem cells, while maintaining strict ethical guidelines.
The hepatitis C therapy peginterferon alfa-2b, when given as low-dose maintenance therapy, can prevent disease progression in certain patients who failed previous interferon-based hepatitis C therapies and have advanced liver disease, according to findings from a large, four-year study presented today at the 43rd annual meeting of the European Association for the Study of the Liver (EASL).
The National Journal assessed President Barack Obama's progress on his health care campaign promises and gave him a score of 47. "As a candidate, Barack Obama made a series of fairly specific promises on health care ($10 billion a year for health IT, loan forgiveness for rural doctors) and drew some bold lines in the sand (universal coverage, prohibitions on insurers from discriminating).
GenSpera, Inc. announced that the first patient was dosed in the ongoing Phase I clinical study of its chemotherapeutic agent, G-202, at the Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio in San Antonio, Texas.
› Verified 7 days ago
Dr. Stephen J. Moses, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 135 Division St, Ansonia, CT 06401 Phone: 203-735-9354 Fax: 203-732-2106 | |
Dr. Chi Tang, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 135 Division St Ste 1, Ansonia, CT 06401 Phone: 203-735-3500 Fax: 203-735-0505 | |
Bruce T Brennan, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 22 Westfield Ave, Ansonia, CT 06401 Phone: 203-734-7100 Fax: 203-734-3392 | |
Sangeetha Rajan, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 111 Wakelee Ave, Ansonia, CT 06401 Phone: 203-308-2781 | |
Mr. Jonathan T Simon, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 22 Westfield Ave, Ansonia, CT 06401 Phone: 203-736-9919 Fax: 203-735-2055 | |
Dr. Aisha Khan, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 111 Wakelee Ave, Ansonia, CT 06401 Phone: 203-308-2781 | |
Dr. Joel S Zaretzky, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 199 Wakelee Ave, Ansonia, CT 06401 Phone: 203-735-5444 Fax: 203-735-1469 |